EARLY RESULTS FROM A PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND EFFICACY OF AMG 404, A PROGRAMMED DEATH-1 (PD-1) ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0

作者：

Price, Timothy ^{[1
]}

Chawla, Sant ^{[2
]}

Falchook, Gerald ^{[3
]}

Prenen, Hans ^{[4
]}

Lugowska, Iwona ^{[5
]}

Subbiah, Vivek ^{[6
]}

Monzon, Jose ^{[7
]}

Ozawa, Yuichi ^{[8
]}

Arkenau, Tobias ^{[9
]}

Lima, Caio Rocha ^{[10
]}

Kuboki, Yasutoshi ^{[11
]}

Nishina, Tomohiro ^{[12
]}

Hui, Mun ^{[13
]}

Rasmussen, Erik ^{[14
]}

Wong, Hansen ^{[14
]}

Najmi, Saltanat ^{[14
]}

Sadraei, Nooshin ^{[14
]}

机构：

[1] Univ Adelaide, Queen Elizabeth Hosp Campus, CALHN, Woodville, SA, Australia

[2] Sarcoma Oncol Ctr, Santa Monica, CA USA

[3] HealthONE, Sarah Cannon Res Inst, Denver, CO USA

[4] Univ Hosp Antwerp, Antwerp, Belgium

[5] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[6] Univ Texas MD Anderson Canc, Houston, TX USA

[7] Tom Baker Canc Clin, Calgary, AB, Canada

[8] Wakayama Med Univ Hosp, Wakayama, Japan

[9] Sarah Cannon Res Inst UK, London, England

[10] Wake Forest Baptist Hlth, Miami, FL USA

[11] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[12] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan

[13] Chris OBrien Lifehouse, Camperdown, NSW, Australia

[14] Amgen Inc, New York, NY USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷

关键词：

D O I：

10.1136/jitc-2020-SITC2020.0403

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

403

引用

页码：A245 / A245

页数：1

共 50 条

[31] Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers
Mislang, A. R. A.
Coward, J.
Cooper, A.
Underhill, C. R.
Zheng, Y.
Xu, N.
Xiao, C.
Jin, X.
Li, B.
Wang, M.
Kwek, K. Y.
Xia, D.
Xia, Y.
Prawira, A.
ANNALS OF ONCOLOGY, 2020, 31 : S1300 - S1301
[32] Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD-1 and VEGF, in Chinese Patients With Advanced Solid Tumors
Wang, Fenghua
Wei, Xiaoli
Zheng, Yulong
Wang, Jing
Ying, Jieer
Chen, Xiaozhong
Luo, Suxia
Luo, Huiyan
Yu, Xufang
Chen, Benchao
Ma, Lei
Xu, Ruihua
CANCER MEDICINE, 2025, 14 (06):
[33] Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors.
Le, Dung T.
Azad, Nilofer Saba
Laheru, Dan
Browner, Ilene S.
Wang, Hao
Uram, Jennifer N.
Kemberling, Holly
Zheng, Lei
Iannone, Robert
Friedman, Evan
Meister, Amy
Donehower, Ross C.
De Jesus-Acosta, Ana
Diaz, Luis A.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[34] PHASE I STUDY OF ANTI PD-1 ANTIBODY ONO-4538 IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
Yamamoto, N.
Nokihara, H.
Yamada, Y.
Asahina, H.
Shibata, T.
Tamura, Y.
Seki, Y.
Honda, K.
Tanabe, Y.
Wakui, H.
Tamura, T.
ANNALS OF ONCOLOGY, 2012, 23 : 26 - 26
[35] A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors
Callahan, Margaret K.
Ott, Patrick Alexander
Odunsi, Kunle
Bertolini, Staphane V.
Pan, Linda S.
Venhaus, Ralph Rudolph
Karakunnel, Joyson Joseph
Hodi, F. Stephen
Wolchok, Jedd D.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[36] Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study.
Shen, Lin
Gong, Jifang
Zhang, Jian
Ji, Dongmei
Zhong, Haijun
Yuan, Ying
Yang, Lei
Zhang, Qingyuan
Li, Yufeng
Wang, Mengde
Qi, Chuan
Xia, Zhenzhong
Lu, Lingmin
Huang, John
Sun, Ling
Xu, Li
Shi, Michael
Hu, Xichun
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[37] Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891
Powderly, J.
Cassier, P. A.
Cervantes, A.
Gao, B.
Gazzah, A.
Italiano, A.
Lin, C-C.
Luke, J. J.
Moreno, V.
Peltola, K.
Rasco, D.
Spira, A. I.
Tanner, M. M. E.
Tosi, D.
Afar, D.
Englert, S.
Parikh, A.
Reddy, A.
Vosganian, G.
Tolcher, A. W.
ANNALS OF ONCOLOGY, 2018, 29 : 144 - 144
[38] Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.
Hamid, Omid
Chow, Laura Quan Man
Tavakkoli, Fatemeh
Marshall, Shannon
Gribbin, Matthew Joseph
Karakunnel, Joyson Joseph
Gray, Jhanelle Elaine
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[39] A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors.
Ott, Patrick Alexander
Callahan, Margaret K.
Odunsi, Kunle
Park, Andrew J.
Pan, Linda S.
Venhaus, Ralph Rudolph
Karakunnel, Joyson Joseph
Hodi, F. Stephen
Wolchok, Jedd D.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[40] Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis
Hong, X.
Zhang, Y.
Chi, Z.
Xu, Q.
Lin, W.
Huang, Y.
Lin, T.
Zhang, Y.
CLINICAL ONCOLOGY, 2024, 36 (01) : e20 - e30

← 1 2 3 4 5 →